ArticleJournal of the West African College of Surgeons
A Comparison of Vitrectomy with and without Intravitreal Methotrexate for Advanced Proliferative Vitreoretinopathy.
Article in Journal of the West African College of Surgeons. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To determine the anatomical visual outcomes and safety of intravitreal (IV) injection of self-compounded methotrexate (MTX) to treat proliferative vitreoretinopathy (PVR), since compounding pharmacies are limited or unavailable locally. Materials and Methods: This was a retrospective comparative, interventional study. Data was obtained from case records and surgical logs. IV MTX compounded in the operating room into aliquots was injected into the vitreous cavity containing silicone oil of eyes after vitrectomy for rhegmatogenous retinal detachment (RRD) complicated with advanced PVR-labelled with methotrexate PVR (WMPVR). Weekly IV MTX at 500 µg/0.1 mL was administered in a fixed dosing regimen in Nigerian PVR patients. The anatomical and visual outcome in WMPVR was compared with two groups matched for age and sex: PVR in which MTX was not used, labelled without MTX PVR (WOMPVR), and retinal detachment without PVR, labelled no PVR (NPVR). The primary outcome was the percentage of retina attachment after a minimum of 6 months follow-up, and the secondary outcome was the change in Snellen best corrected visual acuity conversion to LogMAR. Documented observed complications assessed the safety of IV MTX. Data analysis was done using Statistical Package for the Social Sciences version 22. Means were used for measuring continuous variables and percentages for discrete variables. The three study groups and the two PVR groups were compared. Kruskal-Wallis and Mann-Whitney U were used to calculate the relationship between variables. Results: A total of 90 RRD eyes were studied, 30 in each group. The number of detached quadrants, PVR grade, and macular involvement were similar in WMPVR and WOMPVR ( Conclusion: Preliminary findings demonstrate the safety of self-compounded IV MTX in Nigerians. There was no significant visual improvement despite favourable anatomical outcomes. In this research, a non-PVR group as a standard for comparison of the two PVR groups demonstrates the effectiveness of MTX for PVR by achieving equivalent anatomical outcomes with a group that had no PVR, which had a more favourable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.